Gastrointestinal cancer: Tracking tumour evolution through liquid biopsy

Nature Reviews Clinical Oncology

Volumn 12, Issue 10, 2015, Pages 565-566

  Turajlic, Samra ^a   Swanton, Charles ^a  

^a THE FRANCIS CRICK INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PANITIMUMAB; UNCLASSIFIED DRUG;

BIOPSY TECHNIQUE; CANCER PROGNOSIS; CARCINOGENESIS; CELL FREE SYSTEM; COLORECTAL CANCER; DISEASE COURSE; DNA DETERMINATION; DNA FINGERPRINTING; DNA SEQUENCE; GENE MUTATION; HUMAN; LIQUID BIOPSY; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; RECEPTOR BLOCKING; SHORT SURVEY; TUMOR BIOPSY; ANTAGONISTS AND INHIBITORS; BLOOD; CLONAL EVOLUTION; COLORECTAL TUMOR; DRUG RESISTANCE; GENETICS;

CLONAL EVOLUTION; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84942294285     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.153     Document Type: Short Survey

References (14)

1. Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S., Bardelli, A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 4, 1269-1280 (2014).
2. Esposito, C. et al. The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies. Cancer Biol. Ther. 14, 1143-1146 (2013).
3. Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225-233 (2014).
4. Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21, 795-801 (2015).
5. Diehl, F. et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Natl Acad. Sci. USA 102, 16368-16373 (2005).
6. Diehl, F. et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 14, 985-990 (2008).
7. Tie, J. et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann. Oncol. 26, 1715-1722 (2015).
8. Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532-536 (2012).
9. Diaz, L. A. Jr et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537-540 (2012).
10. Morelli, M. P. et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann. Oncol. 26, 731-736 (2015).
11. Tougeron, D. et al. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann. Oncol. 24, 1267-1273 (2013).
12. Turajlic, S., McGranahan, N., Swanton, C. Inferring mutational timing and reconstructing tumour evolutionary histories. Biochim. Biophys. Acta 1855, 264-275 (2015).
13. Gatenby, R. A., Silva, A. S., Gillies, R. J., Frieden, B. R. Adaptive therapy. Cancer Res. 69, 4894-4903 (2009).
14. Jamal-Hanjani, M. et al. Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. PLoS Biol. 12, e1001906 (2014).